Who we are

TearSolutions, Inc - Natural Therapy for dry eye

President/CEO

Tom R. Gadek, PhD founded and is the former CEO and Board Member of SARcode (later acquired by Shire).  At SARcode he managed corporate strategy and fundraising leading to the discovery and development of Lifitegrast from target identification through lead discovery to clinical proof of concept. This culminated in the approval of Lifitegrast by the FDA in 2016 for the treatment of Dry Eye Disease, now marketed by Shire as Xiidra.

Executive Chairman/Cofounder

Mark B. Logan, is the former Chairman, CEO and President of VISX, Inc. (which invented, obtained FDA approval and commercialized the procedure for correcting refractive vision errors known as LASIK). He is former Senior VP, COO and a member of the board of directors of Bausch & Lomb.

CSO/Cofounder

Gordon W. Laurie, PhD FARVO is Professor of Cell Biology and of Ophthalmology, and a Pinn Scholar at the University of Virginia. He is an Executive Editor of Experimental Eye Research, on the editorial board of Eye & Contact Lens, former member of the Governing Council of the Tear Film and Ocular Surface Society, past winner of the Virginia Biotechnology Association Educator of the Year award, and founder and PI of UVa’s NIH sponsored Biotechnology Training Program.

CTO

John C. Moore, is Chairman of the board of Optovue, a global leader in the ocular optical coherence tomography market. He is the former CEO & President of Laser Diagnostic Technologies (which was acquired by Zeiss) and of Notal Vision, and was Vice President of Business Development at ALCON.

CFO

Colin M. Rolph, is Managing Director of Tall Oaks Capital, LP and is CFO of EpiEp and UVa startup iTiHealth.

Chief Regulatory & Clinical Officer

Michelle Carpenter, JD, RAC is a senior global regulatory affairs professional with 25 years of regulatory experience in the ophthalmology domain, including dry eye. Michelle is former Senior VP of Regulatory Affairs and Clinical Development at Acucela Inc., former Executive Director, Regulatory Affairs at Valeant Pharmaceuticals, and former VP of Global Regulatory Affairs and Project Management at Santen Inc.

Chief Medical Officer/Director

Marc G. Odrich, MD is a practicing ophthalmologist. He is former Medical Director of VISX, Inc. and former Medical Director and Clinical Monitor at Abbott Medical Optics. Dr. Odrich is Associate Professor of Ophthalmology at the University of Virginia. He has written and published on a wide range of ophthalmic issues.

Advisory Board 

Manus C. Kraff, MD is a practicing ophthalmologist and Founder and President of the Kraff Eye Institute. He is a pioneer in the development of intraocular lenses, and Professor of Clinical Ophthalmology at Northwestern University.

Jae K. Lee, PhD is Director of Global Biometrics Sciences at Bristol-Myers Squibb.

J. Daniel Nelson, MD FACS FARVO is a practicing ophthalmologist and Senior Medical Director of HealthPartners Medical Group. He is currently Editor-in-Chief of The Ocular Surface and Chaired the Tear Film and Ocular Surface Society Dry Eye Workshop II Steering Committee.

Kazuo Tsubota, MD PhD FARVO is Chairman of the Department of Ophthalmology at Keio University (Tokyo) with over 500 peer reviewed articles, most on dry eye syndrome and ocular surface physiology. He serves on the Tear Film and Ocular Surface Society Dry Eye Workshop II Steering Committee, is Editor-in-Chief of Aging and Mechanisms of Disease.